BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9177838)

  • 1. New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability.
    Arpicco S; Dosio F; Brusa P; Crosasso P; Cattel L
    Bioconjug Chem; 1997; 8(3):327-37. PubMed ID: 9177838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
    Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
    Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
    Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxin-targeted design for anticancer therapy. I: Synthesis and biological evaluation of new thioimidate heterobifunctional reagents.
    Delprino L; Giacomotti M; Dosio F; Brusa P; Ceruti M; Grosa G; Cattel L
    J Pharm Sci; 1993 May; 82(5):506-12. PubMed ID: 8360828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxin-targeted design for anticancer therapy. II: Preparation and biological comparison of different chemically linked gelonin-antibody conjugates.
    Delprino L; Giacomotti M; Dosio F; Brusa P; Ceruti M; Grosa G; Cattel L
    J Pharm Sci; 1993 Jul; 82(7):699-704. PubMed ID: 8360843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
    Kellogg BA; Garrett L; Kovtun Y; Lai KC; Leece B; Miller M; Payne G; Steeves R; Whiteman KR; Widdison W; Xie H; Singh R; Chari RV; Lambert JM; Lutz RJ
    Bioconjug Chem; 2011 Apr; 22(4):717-27. PubMed ID: 21425776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced stability in vitro and in vivo of immunoconjugates prepared with 5-methyl-2-iminothiolane.
    Carroll SF; Bernhard SL; Goff DA; Bauer RJ; Leach W; Kung AH
    Bioconjug Chem; 1994; 5(3):248-56. PubMed ID: 7918744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
    Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ
    J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages.
    Wright JE; Gittens SA; Bansal G; Kitov PI; Sindrey D; Kucharski C; Uludağ H
    Biomaterials; 2006 Feb; 27(5):769-84. PubMed ID: 16055182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
    Rosenblum MG; Marks JW; Cheung LH
    Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats.
    Worrell NR; Cumber AJ; Parnell GD; Mirza A; Forrester JA; Ross WC
    Anticancer Drug Des; 1986 Nov; 1(3):179-88. PubMed ID: 3502450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Block catiomer polyplexes with regulated densities of charge and disulfide cross-linking directed to enhance gene expression.
    Miyata K; Kakizawa Y; Nishiyama N; Harada A; Yamasaki Y; Koyama H; Kataoka K
    J Am Chem Soc; 2004 Mar; 126(8):2355-61. PubMed ID: 14982439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
    Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC
    Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
    Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
    Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
    Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
    Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA
    Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can metal ions be used as gas-phase disulfide bond cleavage reagents? A survey of coinage metal complexes of model peptides containing an intermolecular disulfide bond.
    Lioe H; Duan M; O'Hair RA
    Rapid Commun Mass Spectrom; 2007; 21(16):2727-33. PubMed ID: 17654640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural features of the antibody-A chain linkage that influence the activity and stability of ricin A chain immunotoxins.
    Cumber AJ; Westwood JH; Henry RV; Parnell GD; Coles BF; Wawrzynczak EJ
    Bioconjug Chem; 1992; 3(5):397-401. PubMed ID: 1329989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.